Azienda Ospedaliera Universitaria Mater Domini
- Address
- Viale Tommaso Campanella 115, 88100 Catanzaro, Italy
Cardiovascular Diseases
At Azienda Ospedaliera Universitaria Mater Domini investigators are exploring primary prevention of atherosclerotic cardiovascular disease by testing a novel RNA‑based agent designed to lower the incidence of major adverse cardiovascular events.
- Primary prevention of ASCVD in high‑risk patients
- Evaluation of long‑acting lipid‑lowering therapy
- Reduction of composite cardiovascular outcomes
The study seeks to demonstrate that sustained treatment can reduce cardiovascular mortality and improve overall patient health.
Digestive System Diseases
Research at the translational oncology unit includes a long‑term assessment of mirikizumab for maintaining remission in patients with ulcerative colitis, as well as a combination immunotherapy trial for metastatic esophageal carcinoma.
- Long‑term therapy to sustain ulcerative colitis remission
- Combination of pembrolizumab and lenvatinib with chemotherapy for esophageal cancer
- Safety and tolerability of novel immunotherapy regimens
These trials aim to enhance disease control, reduce flare frequency, and extend survival for affected individuals.
Neoplasms
The department is evaluating innovative endocrine and targeted strategies in ER+/HER2- early breast cancer with a new selective estrogen receptor degrader, while also testing a multi‑agent regimen in esophageal carcinoma.
- Extended endocrine therapy to prevent breast cancer recurrence
- Combination of pembrolizumab, lenvatinib, and chemotherapy for esophageal carcinoma
- Assessment of overall survival benefits across tumor types
The primary goal is to improve recurrence‑free and overall survival while confirming safety for patients with these malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliera Universitaria Mater Domini
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Jul 2021 | May 2026 |
IMP list
lock Showing 1 of 28 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cisplatin | 2 | Unknown | 2021-07-21 | 2025-01-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.